Seasonal Influenza and Prevention

AUTHORS

Batool Sharifi Mood 1 , * , Farnoosh Sharifi Mood 1 , Roshanak Sharifi 2

1 Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran

2 School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran

How to Cite: Sharifi Mood B, Sharifi Mood F, Sharifi R. Seasonal Influenza and Prevention, Int J Infect. 2016 ; 3(4):e35954. doi: 10.17795/iji-35954.

ARTICLE INFORMATION

International Journal of Infection: 3 (4); e35954
Published Online: June 26, 2016
Article Type: Editorial
Received: December 31, 2015
Revised: January 2, 2016
Accepted: January 2, 2016
Crossmark

Crossmark

CHEKING

READ FULL TEXT

Keywords

Influenza Prevention Vaccination

Copyright © 2016, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Seasonal influenza (or flu) is a very contagious respiratory disease caused by influenza viruses. During May to October of 2015, influenza A (H3N2, H1N1) and influenza B viruses co-circulated world-wide (1). These viruses, particularly H1N1 and H3N2, can cause mild to very severe illness. Serious outcomes of disease and complications can lead to hospitalization and death (2). High-risk individuals are more likely to develop serious complications. High-risk populations include the very young, the elderly, those with chronic renal disease, heart failure, or asthma; and the immune-compromised (cancer or human immunodeficiency virus infection).

The best way to prevent illness is annual vaccination (1, 2). Influenza antiviral medications, as well as vaccination, are recommended for prophylaxis when an unvaccinated patient is high-risk and faced with disease. Antiviral medications are 70% to 90% effective in the prevention of influenza and are useful adjuncts to influenza vaccination (3-5). Vaccination is recommended for the following populations (1, 2):

1- Children younger than 5 years,

2- Adults aged 65 years and older,

3- Persons with chronic pulmonary disease (including asthma); cardiovascular disease (except hypertension alone); renal, hepatic, and hematological disorders including sickle cell anemia; diabetes mellitus; and neurologic diseases including epilepsy, seizure, cerebral palsy, and muscular dystrophy,

4- Persons younger than 19 years, who are receiving long-term aspirin therapy,

5- Persons with immunosuppression, including that caused by medications or by HIV infection,

6- Pregnant women or postpartum mothers (within two weeks after delivery),

7- Residents of nursing homes and other chronic care facilities,

8- Health care staff.

Vaccination is the first and best way to prevent illness. However, a history of flu vaccination cannot rule out the possibility of influenza infection in patients with compatible clinical signs and symptoms. Antiviral treatment is advised within 48 hours of illness onset, not only for high-risk groups, but also for previously healthy symptomatic patients with confirmed or suspected influenza on the basis of clinical judgment (3, 4). Oral oseltamivir, inhaled zanamivir, or intravenous peramivir are the best drugs for treatment of influenza infection. It is possible that some viruses have become resistant to oseltamivir and peramivir, but remain susceptible to zanamivir; this is reported more frequently for influenza A H1N1 viruses (5). Although it is not FDA-approved, the use of oral oseltamivir for treatment of influenza in infants less than 14 days old, and for chemoprophylaxis in infants 3 months to 1 year of age is recommended by the CDC and the American academy of pediatrics (committee on infectious diseases, 2014) (2-5). When a physician employs antiviral drugs, he/she must consider the patient’s age, weight, and renal function, comorbid conditions, indications for drug use (chemoprophylaxis or therapy) and possible interactions with other medications.

Footnote

References

  • 1.

    Adeola OA, Olugasa BO, Emikpe BO. Detection of pandemic strain of influenza virus (A/H1N1/pdm09) in pigs, West Africa: implications and considerations for prevention of future influenza pandemics at the source. Infect Ecol Epidemiol. 2015; 5 : 30227 [DOI][PubMed]

  • 2.

    Ayscue P, Murray E, Uyeki T, Zipprich J, Harriman K, Salibay C, et al. Influenza-associated intensive-care unit admissions and deaths - California, September 29, 2013-January 18, 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(7) : 143 -7 [PubMed]

  • 3.

    Eyler RF, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012; 32(12) : 1061 -9 [DOI][PubMed]

  • 4.

    Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012; 156(7) : 512 -24 [DOI][PubMed]

  • 5.

    Takashita E, Fujisaki S, Kishida N, Xu H, Imai M, Tashiro M, et al. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influenza Other Respir Viruses. 2013; 7(6) : 1390 -9 [DOI][PubMed]

  • COMMENTS

    LEAVE A COMMENT HERE: